Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: October 2007
-
By Donald Zuhn — On August 21, 2007, the U.S. Patent and Trademark Office published new rules concerning continuation and claims practice that will undoubtedly have a profound effect on the way patent attorneys and agents prosecute applications before the Patent Office. In view of the 128-page Federal Register notice regarding the new…
-
By Jason Derry — Anacor Pharmaceuticals and GlaxoSmithKline have announced an agreement relative to discovery, development, and commercialization of therapeutics for viral and bacterial diseases. Anacor develops small molecule therapeutics based on a boron chemistry platform. The agreement provides GlaxoSmithKline the option to select up to four targets for drug candidate development, with…
-
Patent Docs received an e-mail today that contained some interesting information about the impact the new continuation and claims rules might have had if only the Patent Office had promulgated the new rules a "little earlier." We were unable to identify the author online, so if you know who originally penned these two paragraphs, please…
-
By Kevin E. Noonan — The term "the tragedy of the anti-commons" assumed a cache of avant-garde radicalism since its coining by Heller and Eisenberg in 1998. That cache was less alluring the more the listener knew of either patent law or academic science practices, but it certainly attracted "progressive" pundits and policymakers…
-
By Kevin E. Noonan — The Federal Circuit last week clarified two frequently-disputed areas of patent prosecution: how to claim progeny of inventions that inherently self-replicate, and how to appropriately fulfill both the written description and enablement requirements of 35 U.S.C. § 112, first paragraph, and at the same time disclose broadly enough…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Elan Corporation PLC v. Intellipharmaceutics Corporation et al.1:07-cv-00603; filed October 1, 2007 in the District Court of Delaware Infringement of U.S. Patent…
-
October 10-12, 2007 – Stem Cells European Business Summit – Edinburgh, Scotland October 12, 2007 – Intellectual Property Law Summit 2007 (West LEGALWorks and Intellectual Property Law Association of Chicago) – Chicago, IL October 16, 2007 – New Patent Rules Update: Implications of Compliance (World Research Group) October 25-26, 2007 – Biotech and Pharma Public-Private…
-
By Kevin E. Noonan — Among the many new requirements contained in the U.S. Patent and Trademark Office’s recently-promulgated new rules on continuation application filing and claim number restrictions (see links below), the Office has imposed a deadline of February 1, 2008 for all pending applications to satisfy two reporting requirements. First, applicants…
-
By Christopher P. Singer — On August 21, 2007, the U.S. Patent and Trademark Office published new rules concerning continuation and claims practice that will undoubtedly have a profound effect on the way patent attorneys and agents prosecute applications before the Patent Office. In view of the 128-page Federal Register notice regarding the…
-
By Donald Zuhn — On August 21, 2007, the U.S. Patent and Trademark Office published new rules concerning continuation and claims practice that will undoubtedly have a profound effect on the way patent attorneys and agents prosecute applications before the Patent Office. In view of the 128-page Federal Register notice regarding the new…
Patent Docs 